ISRCTN12046333进行中（未招募）未知
A randomised, controlled, single-centre, open-label study to assess the pharmacokinetics of cannabidiol in vapour, oral pouch, edible and chew products in healthy adult subjects
British American Tobacco (United Kingdom)0 个研究点目标入组 36 人开始时间: 2021年1月18日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. 21 to 55 years of age, inclusive, demonstrated by appropriate proof of identification
- •2.1.Body mass index (BMI) of 18.5 to 30.0 kg/m², inclusive.
- •2.2.body weight exceeding 52 kg (males) or 45 kg (females).
- •3. In good health, as judged by the PI or an appropriately qualified designee based on:
- •3.1.Medical history
- •3.2.Physical examination
- •3.3.Vital signs assessment
- •3.4.12-lead ECG
- •3.5.Clinical laboratory evaluations
- •3.6.Lung function tests
- •4. Subjects will have given their written informed consent to participate in the study and will have agreed to abide by the study restrictions
- •5. Subjects must demonstrate the ability to comprehend the informed consent form (ICF), be able to communicate well with the PI or an appropriately qualified designee, understand and comply with the requirements of the study, and be judged suitable for the study in the opinion of the PI or an appropriately qualified designee
- •6. Subjects will be willing to refrain from consuming alcohol within 24 hours prior to admission
- •7. At Screening, subjects must be current experienced vapers and current daily users of CBD with at least 6 months use history. Product use status will be based on subject self reporting and confirmed with product use history questionnaires at screening
- •8. Subjects must be willing to use the study products and use only the products provided to them during clinical confinement, and to abstain from any other CBD product use when instructed
- •9. Female subjects must be of non childbearing potential or must use one of the contraceptive methods
排除标准
- •1. Male subjects who do not agree, or whose partners of childbearing potential do not agree, to use a barrier method of contraception (i.e., a condom with spermicide) in addition to another highly effective method of contraception used by their female partners or to refrain from donating sperm from Admission until at least 90 days after the last product use.
- •2. Female subjects who are pregnant or breastfeeding. This will be confirmed at Screening and Admission. Any female subject who becomes pregnant during this study will be withdrawn.
- •3. Subjects who have donated:
- •3.1.=400 mL of blood within 90 days prior to Admission.
- •3.2.plasma within 90 days prior to Admission.
- •3.3.platelets within 6 weeks prior to Admission.
- •3.4.bone marrow within the last 6 months prior to Admission.
- •4. Subjects who have an acute illness (e.g., upper respiratory tract infection, viral infection, etc.) requiring treatment within 4 weeks prior to Admission.
- •5. Subjects who currently smoke >5 cigarettes per day (or equivalent for other types of tobacco/nicotine containing products) as reported at Screening.
- •6. Subjects who are self-reported non-inhalers (vapers who draw smoke/aerosol from the e-cigarette into the mouth and throat but who do not inhale). Subjects who are determined as non-inhalers at Screening will be excluded.
- •7. Subjects who are planning to quit using CBD products or quit vaping, during the study or postponing a quit attempt in order to participate in the study.
- •8. Presence of braces, partials, dentures, or any dental work that could, in the opinion of the PI, affect the conduct of the study (including missing molars).
- •9. Presence or history of significant form of oral and/or pharyngeal inflammation, oral lesions and/or gum disease or temporomandibular joint dysfunction.
- •10. Subjects who have a significant history of alcoholism or drug/chemical abuse within 24 months prior to Screening, as determined by the PI or an appropriately qualified designee.
- •11. Subjects who have a positive urine drugs of abuse or alcohol screen (confirmed by repeat) at Screening or Admission. Subjects with a positive result for cannabinoids will not be excluded.
- •12. Subjects who have consumed grapefruit, grapefruit juice, Seville oranges, marmalade, pomelo containing products, within 14 days prior to Admission and then throughout the entire study duration.
- •13. Subjects who:
- •13.1. are carriers of the hepatitis B surface antigen (HBsAg)
- •13.2. are carriers of the hepatitis C antibody
- •13.3. have a positive result for the test for human immunodeficiency virus (HIV) antibodies.
- •14. Subjects who have used prescription or over-the-counter (OTC) bronchodilator medication (e.g., inhaled or oral ß adrenergic agonists) to treat a chronic condition within the 12 months prior to Admission and throughout the study.
- •15. Subjects who have received any medications or substances (except for CBD and/or nicotine containing products) which are known to be strong inducers or moderate or strong inhibitors of CYP3A4 or CYP2C19 enzymes and/or P gp within 28 days (for inducers, including St. John’s Wort) or 14 days (for inhibitors) prior to Admissi
研究者
相似试验
进行中（未招募）
Unknown
A study to assess in-the-moment product liking of a heating device with two variants of an alternative non-tobacco, nicotine-containing consumable in healthy adult heated tobacco product usersISRCTN13625876British American Tobacco (United Kingdom)36
进行中（未招募）
Unknown
A study measuring cannabidiol uptake to the bloodstream from novel cannabidiol-containing food productsCBD uptake in healthy adult subjectsISRCTN69161830British American Tobacco (United Kingdom)36
进行中（未招募）
不适用
A single-center, open-label, controlled, randomized study to investigate the impact of a sequential oral contraceptive containing estradiol valerate and dienogest (SH T00658ID) as compared to a sequential oral contraceptive containing ethinylestradiol and levonorgestrel (SH D00264A) on plasma lipids, hemostatic variables, and carbohydrate metabolism in 60 healthy female volunteers aged 18-50 years over 7 treatment cycles - Metabolism study vs Triquilar 21+7ContraceptionEUCTR2004-001614-13-DESchering AG60
已完成
4 期
A single-centre, open-label, randomized controlled trial of efficacy, safety and usability of a basal insulin algorithm incorporated into the GlucoTab system compared to standard care for glycaemic management in geriatric patients with type 2 diabetes at acute geriatric care wardstype 2 diabetesE11Type 2 diabetes mellitusDRKS00012553Medizinische Universität GrazKlinische Abteilung für Endokrinologie und Diabetologie58
进行中（未招募）
1 期
Investigation of efficacy, safety and usability of the GlucoTab system with an integrated long-acting insulin scheme for type 2 diabetes in the geriatric care settingDiabetes mellitus type 2MedDRA version: 19.1 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-000955-25-ATMedical University of Graz80